造影剂肾病的分子影像学诊断和防治进展

摘要: 随着造影剂在现代医学的广泛应用，造影剂肾病（CIN）也引起临床上更多关注。造影剂肾病是指在血管造影或是其他医疗过程中使用碘造影剂引起的急性肾损伤，是仅次于肾灌注不足和肾毒性药物所致肾损伤的医源性急性肾损害的第3大病因。CIN可产生延长住院时间、造成慢性肾功能不全、引起其他血管事件、增加病死率等后果，目前CIN尚无有效的治疗方案，防治重点在于早期评估及预防。本文综述了2014年以来CIN发生的病理生理机制、早期诊断分子标志物、分子影像学诊断、危险因素以及风险预测、造影剂选择、造影剂代谢监测、药物联合水化疗法、基因治疗、中医药治疗、中西医结合治疗等方面的防治进展，以期为CIN的精准诊断和治疗提供参考。
- 造影剂肾病 /
- 造影剂 /
- 分子标志物 /
- 分子影像学 /
- 病理生理机制 /
- 危险因素
Abstract: With the widespread application of contrast agents in modern medicine, contrast induced nephropathy (CIN) has received more attention. As the third most common cause of iatrogenic acute kidney injury after renal hypoperfusion and nephrotoxic medications, CIN refers to acute renal failure due to the administration of the iodinated contrast agents in angiography or other medical procedures. Patients with CIN show prolonged hospitalization, chronic renal insufficiency, other vascular events and higher mortality. At present, there is no effective treatment for CIN and therefor early evaluation and prevention have been the leading focus of CIN treatment. This article reviews the progress in prevention and treatment of CIN since 2014, including pathophysiological mechanisms, molecular markers for early diagnosis, molecular imaging diagnosis, risk factors and risk prediction, contrast agent selection, contrast agent metabolism monitoring, drug combination hydration therapy, gene therapy, traditional Chinese medicine and integrated traditional Chinese medicine and Western medicine.
- contrast induced nephropathy /
- contrast agents /
- molecular markers /
- molecular imaging /
- pathophysiological mechanism /
- risk factors

HTML全文

参考文献(66)

[1]	Solomon R. Improving intravenous fluid therapy for prevention of contrast-induced nephropathy: how to give more without causing heart failure[J]. JACC Cardiovasc Interv, 2016, 9(1): 97-9. doi: 10.1016/j.jcin.2015.10.014
[2]	Chalikias G, Drosos I, Tziakas DN. Contrast-induced acute kidney injury: an update[J]. Cardiovasc Drugs Ther, 2016, 30(2): 215-28. doi: 10.1007/s10557-015-6635-0
[3]	Malik A. Prevention of contrast-induced acute kidney injury[J]. Br J Hosp Med: Lond, 2015, 76(12): 685-9. doi: 10.12968/hmed.2015.76.12.685
[4]	Zuo T, Jiang L, Mao S, et al. Hyperuricemia and contrast-induced acute kidney injury: a systematic review and meta-analysis[J]. Int J Cardiol, 2016, 224: 286-94. doi: 10.1016/j.ijcard.2016.09.033
[5]	Dugbartey GJ, Redington AN. Prevention of contrast-induced nephropathy by limb ischemic preconditioning: underlying mechanisms and clinical effects[J]. Am J Physiol Ren Physiol, 2018, 314(3): F319-28. doi: 10.1152/ajprenal.00130.2017
[6]	Ali-Hasan-al-saegh S, Mirhosseini SJ, Ghodratipour Z, et al. Strategies preventing contrast-induced nephropathy after coronary angiography: a comprehensive meta-analysis and systematic review of 125 randomized controlled trials[J]. Angiology, 2017, 68(5): 389-413. doi: 10.1177/0003319716661445
[7]	马肃爽, 刘志江, 许官学. 造影剂肾病研究进展[J]. 心血管病防治知识, 2017, 7(3): 123-6. doi: 10.3969/j.issn.1672-3015.2017.03.049
[8]	Nijssen EC, Nelemans PJ, Wildberger JE, et al. Contrast-associated acute kidney injury[J]. N Engl J Med, 2019, 381(13): 1295-6.
[9]	Bucher AM, De Cecco CN, Schoepf UJ, et al. Is contrast medium osmolality a causal factor for contrast-induced nephropathy?[J]. Biomed Res Int, 2014, 2014: 931413. http://europepmc.org/abstract/med/24800254
[10]	Kan CY, Ungelenk L, Lupp A, et al. Ischemia-reperfusion injury in aged livers-the energy metabolism, inflammatory response, and autophagy[J]. Transplantation, 2018, 102(3): 368-77. doi: 10.1097/TP.0000000000001999
[11]	Lau A, Chung H, Komada T, et al. Renal immune surveillance and dipeptidase-1 contribute to contrast-induced acute kidney injury[J]. J Clin Invest, 2018, 128(7): 2894-913. doi: 10.1172/JCI96640
[12]	Lu Z, Cheng D, Yin J, et al. Antithrombin Ⅲ protects against contrast-induced nephropathy[J]. EBioMedicine, 2017, 17: 101-7. doi: 10.1016/j.ebiom.2017.02.009
[13]	Yuan Y, Qiu H, Song L, et al. A new risk factor profile for contrast-induced acute kidney injury in patients who underwent an emergency percutaneous coronary intervention[J]. Angiology, 2018, 69(6): 523-31. doi: 10.1177/0003319717736157
[14]	Zhang F, Lu Z, Wang F. Advances in the pathogenesis and prevention of contrast-induced nephropathy[J]. Life Sci, 2020, 259: 118379. doi: 10.1016/j.lfs.2020.118379
[15]	Mironova OI, Deev AD, Lakotka PG, et al. Anemia as a risk factor of contrast-associated acute kidney injury[J]. Terapevticheskii Arkhiv, 2020, 92(12): 48-52. doi: 10.26442/00403660.2020.12.200450
[16]	McCullough PA, Choi JP, Feghali GA, et al. Contrast-induced acute kidney injury[J]. J Am Coll Cardiol, 2016, 68(13): 1465-73. doi: 10.1016/j.jacc.2016.05.099
[17]	Khaleel SA, Raslan NA, Alzokaky AA, et al. Contrast media (meglumine diatrizoate) aggravates renal inflammation, oxidative DNA damage and apoptosis in diabetic rats which is restored by sulforaphane through Nrf2/HO-1 reactivation[J]. Chem Biol Interact, 2019, 309: 108689. doi: 10.1016/j.cbi.2019.06.002
[18]	Liu Y, Liu B, Liu Y, et al. MicroRNA expression profile by next-generation sequencing in a novel rat model of contrast-induced acute kidney injury[J]. Ann Transl Med, 2019, 7(8): 178. doi: 10.21037/atm.2019.04.44
[19]	Liu BW, Chai YF, Guo W, et al. Erratum to microRNA-188 aggravates contrast-induced apoptosis by targeting SRSF7 in novel isotonic contrast-induced acute kidney injury rat models and renal tubular epithelial cells[J]. Ann Transl Med, 2021, 9(3): 275. doi: 10.21037/atm-2020-45
[20]	Liao B, Nian W, Xi A, et al. Evaluation of a diagnostic test of serum neutrophil gelatinase-associated lipocalin (NGAL) and urine KIM-1 in contrast-induced nephropathy (CIN)[J]. Med Sci Monit, 2019, 25: 565-70. doi: 10.12659/MSM.912569
[21]	Connolly M, Kinnin M, McEneaney D, et al. Prediction of contrast induced acute kidney injury using novel biomarkers following contrast coronary angiography[J]. QJM, 2018, 111(2): 103-10. doi: 10.1093/qjmed/hcx201
[22]	Yegenaga I, Kamis F, Baydemir C, et al. Neutrophil gelatinase-associated lipocalin is a better biomarker than cystatin C for the prediction of imminent acute kidney injury in critically ill patients[J]. Ann Clin Biochem, 2018, 55(2): 190-7. doi: 10.1177/0004563217694051
[23]	Gu G, Yu N, Zhou Y, et al. Elevation of preoperative cystatin C as an early predictor of contrast-induced nephropathy in patients receiving percutaneous coronary intervention[J]. Smedj, 2021. DOI: 10.11622/smedj.2021002.
[24]	Chen CT, Chang LY, Chuang CW, et al. Optimal measuring timing of cystatin C for early detection of contrast-induced acute kidney injury: a systematic review and meta-analysis[J]. Toxicol Lett, 2020, 318: 65-73. doi: 10.1016/j.toxlet.2019.10.011
[25]	Yoneyama F, Okamura T, Takigiku K, et al. Novel urinary biomarkers for acute kidney injury and prediction of clinical outcomes after pediatric cardiac surgery[J]. Pediatr Cardiol, 2020, 41(4): 695-702. doi: 10.1007/s00246-019-02280-3
[26]	Malyszko J, Bachorzewska-Gajewska H, Koc-Zorawska E, et al. Midkine: a novel and early biomarker of contrast-induced acute kidney injury in patients undergoing percutaneous coronary interventions[J]. Biomed Res Int, 2015, 2015: 879509. http://europepmc.org/articles/pmc4299314/
[27]	Wybraniec MT, Chudek J, Bożentowicz-Wikarek M, et al. Prediction of contrast-induced acute kidney injury by early post-procedural analysis of urinary biomarkers and intra-renal Doppler flow indices in patients undergoing coronary angiography[J]. J Interven Cardiol, 2017, 30(5): 465-72. doi: 10.1111/joic.12404
[28]	Wang Y, Liu K, Xie X, et al. Contrast-associated acute kidney injury: an update of risk factors, risk factor scores, and preventive measures[J]. Clin Imaging, 2021, 69: 354-62. doi: 10.1016/j.clinimag.2020.10.009
[29]	Kanbay M, Siriopol D, Ozdogan E, et al. Serum osmolarity as a potential predictor for contrast-induced nephropathy following elective coronary angiography[J]. Int Urol Nephrol, 2020, 52(3): 541-7. doi: 10.1007/s11255-020-02391-4
[30]	McDonald JS, McDonald RJ, Williamson EE, et al. Is intravenous administration of iodixanol associated with increased risk of acute kidney injury, dialysis, or mortality? A propensity score-adjusted study[J]. Radiology, 2017, 285(2): 414-24. doi: 10.1148/radiol.2017161573
[31]	Barbieri L, Verdoia M, Marino P, et al. Contrast volume to creatinine clearance ratio for the prediction of contrast-induced nephropathy in patients undergoing coronary angiography or percutaneous intervention[J]. Eur J Prev Cardiol, 2016, 23(9): 931-7. doi: 10.1177/2047487315614493
[32]	Wichmann JL, Katzberg RW, Litwin SE, et al. Contrast-induced nephropathy[J]. Circulation, 2015, 132(20): 1931-6. doi: 10.1161/CIRCULATIONAHA.115.014672
[33]	Mehran R, Dangas GD, Weisbord SD. Contrast-associated acute kidney injury. reply[J]. N Engl J Med, 2019, 381(13): 1296-7.
[34]	王心镜, 刘平玲, 曹雪, 等. 造影剂温度对经皮冠状动脉介入治疗患者造影剂肾病发病率的影响[J]. 心脏杂志, 2017, 29(2): 198-201, 205. https://www.cnki.com.cn/Article/CJFDTOTAL-XGNZ201702017.htm
[35]	Hossain MA, Costanzo E, Cosentino J, et al. Contrast-induced nephropathy: Pathophysiology, risk factors, and prevention[J]. Saudi J Kidney Dis Transpl, 2018, 29(1): 1-9. doi: 10.4103/1319-2442.225199
[36]	Sedhai YR, Golamari R, Timalsina S, et al. Contrast-induced nephropathy after cardiac catheterization: culprits, consequences and predictors[J]. Am J Med Sci, 2017, 354(5): 462-6. doi: 10.1016/j.amjms.2017.05.010
[37]	张萍, 张虹, 曹振华, 等. 急性冠脉综合征患者PCI术后造影剂肾病危险因素分析[J]. 山东医药, 2014, 54(17): 64-6. doi: 10.3969/j.issn.1002-266X.2014.17.026
[38]	Older RA, Korobkin M, Cleeve DM, et al. Contrast-induced acute renal failure: persistent nephrogram as clue to early detection[J]. Am J Roentgenol, 1980, 134(2): 339-42. doi: 10.2214/ajr.134.2.339
[39]	Shin H, Taghavifar S, Salehi S, et al. Current comments on contrast media administration in patients with renal insufficiency[J]. Clin Imaging, 2021, 69: 37-44. doi: 10.1016/j.clinimag.2020.06.040
[40]	Gao YM, Li D, Cheng H, et al. Derivation and validation of a risk score for contrast-induced nephropathy after cardiac catheterization in Chinese patients[J]. Clin Exp Nephrol, 2014, 18(6): 892-8. doi: 10.1007/s10157-014-0942-9
[41]	Chen YL, Fu NK, Xu J, et al. A simple preprocedural score for risk of contrast-induced acute kidney injury after percutaneous coronary intervention[J]. Catheter Cardiovasc Interv, 2014, 83(1): E8-16. doi: 10.1002/ccd.25109
[42]	Eng J, Wilson RF, Subramaniam RM, et al. Comparative effect of contrast media type on the incidence of contrast-induced nephropathy: a systematic review and meta-analysis[J]. Ann Intern Med, 2016, 164(6): 417-24. doi: 10.7326/M15-1402
[43]	张劭彦. 等渗及低渗造影剂对高危患者发生造影剂肾病的对比[J]. 中国医药科学, 2018, 8(11): 207-9. https://www.cnki.com.cn/Article/CJFDTOTAL-GYKX201811062.htm
[44]	李茜, 邢建峰, 王丰, 等. 非离子型与离子型对比剂不良反应及对肾功能指标影响观察[J]. 药物流行病学杂志, 2018, 27(8): 518-21. https://www.cnki.com.cn/Article/CJFDTOTAL-YWLX201808006.htm
[45]	贺大春, 舒成, 姜金爱, 等. 不同温度非离子型造影剂对冠脉介入术中不良反应及术后肾功能和凝血功能的影响[J]. 中国现代医药杂志, 2019, 21(10): 6-10. doi: 10.3969/j.issn.1672-9463.2019.10.002
[46]	刘琼. 非离子型造影剂在CT增强扫描中不良反应的防治与护理研究[J]. 世界最新医学信息文摘, 2015, 15(96): 199, 202. https://www.cnki.com.cn/Article/CJFDTOTAL-WMIA201596137.htm
[47]	齐茸茸. 口服水化疗法在胰腺癌患者强化CT造影剂排泄中的应用性研究[D]. 天津: 天津医科大学, 2018.
[48]	Alshogran OY, Nusair SD, El-Elimat T, et al. Evaluation of coenzyme Q10 combined with or without N-acetyl cysteine or atorvastatin for preventing contrast-induced kidney injury in diabetic rats[J]. Naunyn Schmiedeberg's Arch Pharmacol, 2021: 1-8. doi: 10.1007/s00210-021-02070-w
[49]	Xie J, Jiang M, Lin Y, et al. Re: effect of alprostadil in the prevention of contrast-induced nephropathy: a meta-analysis of 36 randomized controlled trials[J]. Angiology, 2020, 71(1): 97. doi: 10.1177/0003319719870398
[50]	Zhou F, Song W, Wang Z, et al. Effects of remote ischemic preconditioning on contrast induced nephropathy after percutaneous coronary intervention in patients with acute coronary syndrome[J]. Medicine: Baltimore, 2018, 97(2): e9579. doi: 10.1097/MD.0000000000009579
[51]	郭素箴, 菅练, 程德刚, 等. 远端缺血预适应对老年非ST段抬高型心肌梗死患者造影剂肾病保护作用的研究[J]. 中华老年心脑血管病杂志, 2019, 21(12): 1269-72. doi: 10.3969/j.issn.1009-0126.2019.12.010
[52]	Putzu A, Boscolo Berto M, Belletti A, et al. Prevention of contrast-induced acute kidney injury by furosemide with matched hydration in patients undergoing interventional procedures: a systematic review and meta-analysis of randomized trials[J]. JACC: Cardiovasc Interv, 2017, 10(4): 355-63. doi: 10.1016/j.jcin.2016.11.006
[53]	Briguori C, D'Amore C, De Micco F, et al. Renal insufficiency following contrast media administration trial Ⅲ: Urine flow rateguided versus left-ventricular end-diastolic pressure-guided hydration in high-risk patients for contrast-induced acute kidney injury. Rationale and design[J]. Catheter Cardiovasc Interv, 2020, 95(5): 895-903. doi: 10.1002/ccd.28386
[54]	Liu XL, Song W, Zhang XM, et al. Downregulating LncRNA XIST attenuated contrast-induced nephropathy injury via regulating miR-133a-3p/NLRP3 axis[J]. J Thromb Thrombolysis, 2021(1): 1-14. http://www.researchgate.net/publication/348162184_Downregulating_LncRNA_XIST_attenuated_contrast-induced_nephropathy_injury_via_regulating_miR-133a-3pNLRP3_axis
[55]	Adly AA, Ismail EA, Andrawes NG, et al. Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease[J]. Cytokine, 2016, 79: 52-8. doi: 10.1016/j.cyto.2015.12.022
[56]	戈立秀, 赵凯, 高巧营, 等. 山莨菪碱联合普罗布考对糖尿病大鼠造影剂肾损伤凋亡基因FAS/FASL表达的影响[J]. 中国实验诊断学, 2018, 22(6): 1049-53. doi: 10.3969/j.issn.1007-4287.2018.06.038
[57]	Hubbard PA, Moody CL, Murali R. Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities[J]. Front Physiol, 2014, 5: 478. http://www.ncbi.nlm.nih.gov/pubmed/25566081
[58]	陆明, 胡鹏飞, 林冬铭, 等. 消瘀泄浊饮对造影剂肾病大鼠保护作用的实验研究[J]. 中国现代医生, 2019, 57(2): 37-40, 169. https://www.cnki.com.cn/Article/CJFDTOTAL-ZDYS201902010.htm
[59]	王东芳. 急诊PCI术后造影剂肾病的证素特征及八珍汤的疗效评价研究[D]. 北京: 中国中医科学院, 2018.
[60]	宗春辉, 赵凯, 张琦, 等. 冬虫夏草预防糖尿病大鼠对比剂肾病机制研究[J]. 中国中西医结合杂志, 2020, 40(2): 204-10. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ202002019.htm
[61]	齐春霞, 吴伟, 褚庆民, 等. 丹红注射液联合水化预防造影剂肾病疗效的系统评价与meta分析[J]. 中西医结合心脑血管病杂志, 2017, 15 (5): 570-3. doi: 10.3969/j.issn.1672-1349.2017.05.016
[62]	许潜, 钟周, 杨进, 等. 黄芪四物汤对碘造影剂肾病大鼠的保护作用及机制研究[J]. 时珍国医国药, 2019, 30(7): 1537-40. https://www.cnki.com.cn/Article/CJFDTOTAL-SZGY201907001.htm
[63]	赵凯, 许蔚, 陈卓阳. 针刺治疗对2型糖尿病患者对比剂肾病的预防作用[J]. 中国中医基础医学杂志, 2018, 24(3): 382-4. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC201803032.htm
[64]	王大鹏, 闫红霞, 周立宾, 等. 金水宝胶囊联合瑞舒伐他汀治疗经皮冠状动脉介入治疗术后并发造影剂肾病临床观察[J]. 中国药业, 2020, 29(16): 90-2. doi: 10.3969/j.issn.1006-4931.2020.16.029
[65]	玄进, 李振勇. 五苓散联合前列地尔预防冠心病患者经皮冠状动脉介入术后造影剂肾病发生率的影响[J]. 辽宁中医杂志, 2020, 47(9): 83-6. https://www.cnki.com.cn/Article/CJFDTOTAL-LNZY202009028.htm
[66]	翟小菊, 李松林, 张楚珺. 黄葵胶囊联合前列地尔注射液对造影剂肾病的预防作用[J]. 河南大学学报: 医学版, 2019, 38(4): 258-60. https://www.cnki.com.cn/Article/CJFDTOTAL-KFYZ201904008.htm

施引文献

资源附件(0)

访问统计

点击查看大图

计量

文章访问数: 469
HTML全文浏览量: 172
PDF下载量: 7
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

造影剂肾病的分子影像学诊断和防治进展

doi: 10.12122/j.issn.1674-4500.2021.04.29

作者简介:
刘之荷，在读硕士研究生，E-mail: lotusleo1995@163.com

通讯作者:
万辛，博士，主任医师，E-mail: wanxin@njmu.edu.cn

计量

Progresses in molecular imaging diagnosis, prevention and treatment for contrast-induced nephropathy

计量

目录

留言板

造影剂肾病的分子影像学诊断和防治进展

doi: 10.12122/j.issn.1674-4500.2021.04.29

作者简介: 刘之荷，在读硕士研究生，E-mail: lotusleo1995@163.com

通讯作者: 万辛，博士，主任医师，E-mail: wanxin@njmu.edu.cn

计量

出版历程

Progresses in molecular imaging diagnosis, prevention and treatment for contrast-induced nephropathy

计量

出版历程

目录

作者简介:
刘之荷，在读硕士研究生，E-mail: lotusleo1995@163.com

通讯作者:
万辛，博士，主任医师，E-mail: wanxin@njmu.edu.cn